{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:55:51Z","timestamp":1792742151102,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001787","name":"University of South Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001787","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Long-acting injectables have gained attraction as a system for treating chronic conditions due to their increased efficacy, safety, and patient compliance. Currently, patients with Parkinsons need to administer oral medications multiple times a day which imposes the significant risk of non-compliance. This study aimed to design an in-situ implant-forming system for controlled delivery of levodopa and carbidopa for up to 1 week which will reduce the need for multiple dosing. The combination of poly-lactic-co-glycolic acid (PLGA <jats:sub>50:50<\/jats:sub>) and Eudragit L-100 was used to prepare the implants and the formulation was optimized to achieve a controlled release over 7 days. The optimized formulation containing 26% PLGA and 6% Eudragit L 100 displayed a favorable release profile and injectability with low viscosity. The optimized formulation in vitro release study revealed an initial burst of 34.17% and 37.16% for levodopa and carbidopa in the first 24\u00a0h and about 92% and 81% release within 7 days. A good correlation was observed between the in-vitro drug release data and ex-vivo drug release with a correlation coefficient of 0.91 for levodopa and 0.90 for carbidopa. Viscosity analysis showed the Newtonian behavior of the formulation. Syringeability analysis of the formulation showed that the maximum force required for expelling the formulation was 32.98\u2009\u00b1\u20090.72\u00a0N using a 22 G needle. The in-vitro degradation studies revealed 81.89% weight loss of implant in 7 days. The prepared formulation was assessed for in-vivo performance using a convolution modeling technique using a convolve function in R software. The predicted AUC 0-\u221e h for the in-situ forming implant was 26505.5 ng\/ml with Cmax, 399.3 ng\/ml, and Tmax 24\u00a0h assuming 100% bioavailability. The results justify that the prepared in-situ implant forming system can be a promising system for the delivery of levodopa and carbidopa for Parkinson\u2019s patients.<\/jats:p>","DOI":"10.1007\/s13346-025-01892-y","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:28:05Z","timestamp":1749295685000},"page":"4026-4042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson\u2019s disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Deepa D.","family":"Nakmode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadikalmahdi","family":"Abdella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-2629","authenticated-orcid":false,"given":"Sanjay","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"1892_CR1","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease (2023, accessed 20\/03 2025)."},{"key":"1892_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.20517\/2347-8659.2020.58","volume":"8","author":"TK Lee","year":"2021","unstructured":"Lee TK, Yankee EL. A review on Parkinson\u2019s disease treatment. Neuroimmunol Neuroinflamm. 2021;8:222\u201344.","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"1892_CR3","first-page":"679","volume":"102","author":"AD Halli-Tierney","year":"2020","unstructured":"Halli-Tierney AD, Luker J, Carroll DG. Parkinson Disease. Am Fam Physician. 2020;102:679\u201391.","journal-title":"Am Fam Physician"},{"key":"1892_CR4","doi-asserted-by":"publisher","unstructured":"Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem. 2016;139(Suppl 1):325\u2013337. 20160830. https:\/\/doi.org\/10.1111\/jnc.13750","DOI":"10.1111\/jnc.13750"},{"key":"1892_CR5","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1517\/17425247.2.6.1059","volume":"2","author":"TH Johnston","year":"2005","unstructured":"Johnston TH, Fox SH, Brotchie JM. Advances in the delivery of treatments for Parkinson\u2019s disease. Expert Opin Drug Deliv. 2005;2:1059\u201373. https:\/\/doi.org\/10.1517\/17425247.2.6.1059.","journal-title":"Expert Opin Drug Deliv"},{"key":"1892_CR6","doi-asserted-by":"publisher","first-page":"20230515","DOI":"10.3390\/pharmaceutics15051503","volume":"15","author":"DD Nakmode","year":"2023","unstructured":"Nakmode DD, Day CM, Song Y, et al. The Management of Parkinson\u2019s Disease: An Overview of the Current Advancements in Drug Delivery Systems. Pharmaceutics. 2023;15:20230515. https:\/\/doi.org\/10.3390\/pharmaceutics15051503.","journal-title":"Pharmaceutics"},{"key":"1892_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe S, Mader K. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J Control Release. 2012;161:668\u201367920120418. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.016.","journal-title":"J Control Release"},{"key":"1892_CR8","unstructured":"Vanderbilt RLDPERCP. Biodegradable in-situ forming implants and methods of producing the same. US; 1995."},{"key":"1892_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ejps.2011.09.011","volume":"44","author":"S Abashzadeh","year":"2011","unstructured":"Abashzadeh S, Dinarvand R, Sharifzadeh M, et al. Formulation and evaluation of an in situ gel forming system for controlled delivery of triptorelin acetate. Eur J Pharm Sci. 2011;44:514\u201352120110916. https:\/\/doi.org\/10.1016\/j.ejps.2011.09.011.","journal-title":"Eur J Pharm Sci"},{"issue":"20131227","key":"1892_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2013.12.020","volume":"176","author":"RR Thakur","year":"2014","unstructured":"Thakur RR, McMillan HL, Jones DS. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J Control Release. 2014;176(20131227):8\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2013.12.020.","journal-title":"J Control Release"},{"key":"1892_CR11","doi-asserted-by":"publisher","unstructured":"Ibrahim HM, Ahmed TA, Hussain MD et al. Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev Ind Pharm. 2014;40(20130109):66\u201373. https:\/\/doi.org\/10.3109\/03639045.2012.746360","DOI":"10.3109\/03639045.2012.746360"},{"key":"1892_CR12","doi-asserted-by":"crossref","unstructured":"Amini-Fazl MS. Biodegradation study of PLGA as an injectable in situ depot-forming implant for controlled release of paclitaxel. Polym Bull. 2021;79:1\u201314.","DOI":"10.1007\/s00289-020-03347-5"},{"key":"1892_CR13","doi-asserted-by":"publisher","first-page":"120105","DOI":"10.1016\/j.ijpharm.2020.120105","volume":"592","author":"MS Suh","year":"2021","unstructured":"Suh MS, Kastellorizios M, Tipnis N, et al. Effect of implant formation on drug release kinetics of in situ forming implants. Int J Pharm. 2021;592:120105. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120105.","journal-title":"Int J Pharm"},{"key":"1892_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1208\/s12249-008-9126-9","volume":"9","author":"HA Gad","year":"2008","unstructured":"Gad HA, El-Nabarawi MA, El-Hady A. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and\/or doxycycline for treatment of periodontitis. AAPS PharmSciTech. 2008;9:878\u201388420080725. https:\/\/doi.org\/10.1208\/s12249-008-9126-9.","journal-title":"AAPS PharmSciTech"},{"key":"1892_CR15","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1002\/jps.23250","volume":"101","author":"TA Ahmed","year":"2012","unstructured":"Ahmed TA, Ibrahim HM, Ibrahim F, et al. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. J Pharm Sci. 2012;101:3753\u201362. https:\/\/doi.org\/10.1002\/jps.23250.","journal-title":"J Pharm Sci"},{"issue":"20120113","key":"1892_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijpharm.2012.01.005","volume":"426","author":"DN Kapoor","year":"2012","unstructured":"Kapoor DN, Katare OP, Dhawan S. In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor. Int J Pharm. 2012;426(20120113):132\u201343. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.01.005.","journal-title":"Int J Pharm"},{"key":"1892_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijpharm.2018.07.013","volume":"548","author":"C Bode","year":"2018","unstructured":"Bode C, Kranz H, Siepmann F, et al. In-situ forming PLGA implants for intraocular dexamethasone delivery. Int J Pharm. 2018;548:337\u201348. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.07.013.","journal-title":"Int J Pharm"},{"key":"1892_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/17425247.2.6.1039","volume":"2","author":"Y Shi","year":"2005","unstructured":"Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv. 2005;2:1039\u201358. https:\/\/doi.org\/10.1517\/17425247.2.6.1039.","journal-title":"Expert Opin Drug Deliv"},{"key":"1892_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","volume":"172","author":"M Parent","year":"2013","unstructured":"Parent M, Nouvel C, Koerber M, et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J Control Release. 2013;172:292\u2013304. https:\/\/doi.org\/10.1016\/j.jconrel.2013.08.024.","journal-title":"J Control Release"},{"key":"1892_CR20","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s13346-024-01747-y","volume":"15","author":"DD Nakmode","year":"2025","unstructured":"Nakmode DD, Singh B, Abdella S, et al. Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies. Drug Deliv Transl Res. 2025;15:1156\u201380. https:\/\/doi.org\/10.1007\/s13346-024-01747-y.","journal-title":"Drug Deliv Transl Res"},{"key":"1892_CR21","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/jnnp.2004.035980","volume":"76","author":"AH Schapira","year":"2005","unstructured":"Schapira AH. Present and future drug treatment for Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2005;76:1472\u20138. https:\/\/doi.org\/10.1136\/jnnp.2004.035980.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1892_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1055\/s-0037-1601888","volume":"37","author":"A Tarakad","year":"2017","unstructured":"Tarakad A, Jankovic J. Diagnosis and Management of Parkinson\u2019s Disease. Semin Neurol. 2017;37:118\u201326. https:\/\/doi.org\/10.1055\/s-0037-1601888.","journal-title":"Semin Neurol"},{"key":"1892_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/ph14010066","volume":"14","author":"M Haider","year":"2021","unstructured":"Haider M, Elsayed I, Ahmed IS, et al. In situ-forming microparticles for controlled release of rivastigmine: in vitro optimization and in vivo evaluation. Pharmaceuticals. 2021;14:66.","journal-title":"Pharmaceuticals"},{"key":"1892_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s0939-6411(00)00099-0","volume":"50","author":"HB Ravivarapu","year":"2000","unstructured":"Ravivarapu HB, Burton K, DeLuca. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm. 2000;50:263\u201370. https:\/\/doi.org\/10.1016\/s0939-6411(00)00099-0.","journal-title":"Eur J Pharm Biopharm"},{"key":"1892_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1163\/156856295x00175","volume":"6","author":"E Piskin","year":"1995","unstructured":"Piskin E. Biodegradable polymers as biomaterials. J Biomater Sci Polym Ed. 1995;6:775\u201395. https:\/\/doi.org\/10.1163\/156856295x00175.","journal-title":"J Biomater Sci Polym Ed"},{"key":"1892_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0378-5173(02)00431-3","volume":"248","author":"MJ Dorta","year":"2002","unstructured":"Dorta MJ, Santovena A, Llabres M, et al. Potential applications of PLGA film-implants in modulating in vitro drugs release. Int J Pharm. 2002;248:149\u201356. https:\/\/doi.org\/10.1016\/s0378-5173(02)00431-3.","journal-title":"Int J Pharm"},{"key":"1892_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4155\/tde.14.91","volume":"6","author":"DN Kapoor","year":"2015","unstructured":"Kapoor DN, Bhatia A, Kaur R, et al. PLGA: a unique polymer for drug delivery. Ther Deliv. 2015;6:41\u201358. https:\/\/doi.org\/10.4155\/tde.14.91.","journal-title":"Ther Deliv"},{"key":"1892_CR28","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.xphs.2020.11.006","volume":"110","author":"F Karp","year":"2021","unstructured":"Karp F, Turino LN, Helbling IM, et al. In situ Formed Implants, Based on PLGA and Eudragit Blends, for Novel Florfenicol Controlled Release Formulations. J Pharm Sci. 2021;110:1270\u2013127820201118. https:\/\/doi.org\/10.1016\/j.xphs.2020.11.006.","journal-title":"J Pharm Sci"},{"key":"1892_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1208\/s12249-014-0101-3","volume":"15","author":"TA Ahmed","year":"2014","unstructured":"Ahmed TA, Ibrahim HM, Samy AM, et al. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability. AAPS PharmSciTech. 2014;15:772\u201380. https:\/\/doi.org\/10.1208\/s12249-014-0101-3.","journal-title":"AAPS PharmSciTech"},{"key":"1892_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13065-025-01410-8","volume":"19","author":"DD Nakmode","year":"2025","unstructured":"Nakmode DD, Youssef SH, Das S, et al. Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC. BMC Chem. 2025;19:43. https:\/\/doi.org\/10.1186\/s13065-025-01410-8.","journal-title":"BMC Chem"},{"key":"1892_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123\u201333. https:\/\/doi.org\/10.1016\/s0928-0987(01)00095-1.","journal-title":"Eur J Pharm Sci"},{"key":"1892_CR32","doi-asserted-by":"publisher","unstructured":"Patel RB, Solorio L, Wu H et al. Effect of injection site on in situ implant formation and drug release in vivo. J Control Release. 2010;147:350\u2013358. 20100820. https:\/\/doi.org\/10.1016\/j.jconrel.2010.08.020","DOI":"10.1016\/j.jconrel.2010.08.020"},{"key":"1892_CR33","doi-asserted-by":"publisher","first-page":"13728","DOI":"10.1039\/d3nr01789c","volume":"15","author":"F Abid","year":"2023","unstructured":"Abid F, Savaliya B, Parikh A, et al. Nanotechnology and narasin: a powerful combination against acne. Nanoscale. 2023;15:13728\u201339. https:\/\/doi.org\/10.1039\/d3nr01789c.","journal-title":"Nanoscale"},{"key":"1892_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12917-023-03596-2","volume":"19","author":"Y Song","year":"2023","unstructured":"Song Y, Abdella S, Afinjuomo F, et al. Physicochemical properties of otic products for Canine Otitis Externa: comparative analysis of marketed products. BMC Vet Res. 2023;19:39. https:\/\/doi.org\/10.1186\/s12917-023-03596-2.","journal-title":"BMC Vet Res"},{"key":"1892_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jpba.2017.11.065","volume":"150","author":"Y Sun","year":"2018","unstructured":"Sun Y, Jensen H, Petersen NJ, et al. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging. J Pharm Biomed Anal. 2018;150:95\u2013106. https:\/\/doi.org\/10.1016\/j.jpba.2017.11.065.","journal-title":"J Pharm Biomed Anal"},{"key":"1892_CR36","doi-asserted-by":"publisher","first-page":"123790","DOI":"10.1016\/j.ijpharm.2024.123790","volume":"651","author":"SH Youssef","year":"2024","unstructured":"Youssef SH, Ganesan R, Amirmostofian M, et al. Printing a cure: A tailored solution for localized drug delivery in liver cancer treatment. Int J Pharm. 2024;651:123790. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123790.","journal-title":"Int J Pharm"},{"key":"1892_CR37","doi-asserted-by":"crossref","unstructured":"Ge J, Li M, Zhang Q et al. Silica aerogel improves the biocompatibility in a poly\u2013caprolactone composite used as a tissue engineering scaffold. Int J Polym Sci. 2013;2013.","DOI":"10.1155\/2013\/402859"},{"key":"1892_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/17460441.3.6.655","volume":"3","author":"AL Niles","year":"2008","unstructured":"Niles AL, Moravec RA, Riss TL. Update on in vitro cytotoxicity assays for drug development. Expert Opin Drug Discov. 2008;3:655\u201369. https:\/\/doi.org\/10.1517\/17460441.3.6.655.","journal-title":"Expert Opin Drug Discov"},{"key":"1892_CR39","doi-asserted-by":"publisher","unstructured":"Tan JM, Saifullah B, Kura AU, et al. Incorporation of Levodopa into Biopolymer Coatings Based on Carboxylated Carbon Nanotubes for pH-Dependent Sustained Release Drug Delivery. Nanomaterials (Basel). 2018;820180531. https:\/\/doi.org\/10.3390\/nano8060389.","DOI":"10.3390\/nano8060389"},{"key":"1892_CR40","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/IJN.S39740","volume":"8","author":"AU Kura","year":"2013","unstructured":"Kura AU, Hussein Al Ali SH, Hussein MZ, et al. Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomed. 2013;8:1103\u201310. https:\/\/doi.org\/10.2147\/IJN.S39740.","journal-title":"Int J Nanomed"},{"key":"1892_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jddst.2019.01.011","volume":"50","author":"H Kamali","year":"2019","unstructured":"Kamali H, Khodaverdi E, Hadizadeh F, et al. Comparison of in-situ forming composite using PLGA-PEG-PLGA with in-situ forming implant using PLGA: In-vitro, ex-vivo, and in-vivo evaluation of naltrexone release. J Drug Deliv Sci Technol. 2019;50:188\u2013200.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1892_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2125.1989.tb03506.x","volume":"28","author":"DR Robertson","year":"1989","unstructured":"Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989;28:61\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03506.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1892_CR43","doi-asserted-by":"publisher","first-page":"20220228","DOI":"10.3390\/pharmaceutics14030542","volume":"14","author":"S Abdella","year":"2022","unstructured":"Abdella S, Afinjuomo F, Song Y, et al. Mucoadhesive Buccal Film of Estradiol for Hormonal Replacement Therapy: Development and In-Vivo Performance Prediction. Pharmaceutics. 2022;14:20220228. https:\/\/doi.org\/10.3390\/pharmaceutics14030542.","journal-title":"Pharmaceutics"},{"key":"1892_CR44","doi-asserted-by":"publisher","first-page":"105948","DOI":"10.1016\/j.jct.2019.105948","volume":"141","author":"V Verma","year":"2020","unstructured":"Verma V, Awasthi A, Awasthi A. Physicochemical investigations of polyethylene glycols with N, N dimethylacetamide. J Chem Thermodyn. 2020;141:105948.","journal-title":"J Chem Thermodyn"},{"key":"1892_CR45","doi-asserted-by":"publisher","first-page":"104300","DOI":"10.1016\/j.jddst.2023.104300","volume":"81","author":"SH Youssef","year":"2023","unstructured":"Youssef SH, Kim S, Khetan R, et al. The development of 5-fluorouracil biodegradable implants: A comparative study of PCL\/PLGA blends. J Drug Deliv Sci Technol. 2023;81:104300.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1892_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijpharm.2011.03.051","volume":"418","author":"J Siepmann","year":"2011","unstructured":"Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011;418:6\u201312. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.03.051.","journal-title":"Int J Pharm"},{"key":"1892_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijpharm.2005.07.022","volume":"304","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Kanbe H, Okada M, et al. Formulation study and drug release mechanism of a new theophylline sustained-release preparation. Int J Pharm. 2005;304:91\u2013101.","journal-title":"Int J Pharm"},{"key":"1892_CR48","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/jps.2600551113","volume":"55","author":"SJ Desai","year":"1966","unstructured":"Desai SJ, Singh P, Simonelli AP, et al. Investigation of factors influencing release of solid drug dispersed in inert matrices. 3. Quantitative studies involving the polyethylene plastic matrix. J Pharm Sci. 1966;55:1230\u20134. https:\/\/doi.org\/10.1002\/jps.2600551113.","journal-title":"J Pharm Sci"},{"key":"1892_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijpharm.2010.10.037","volume":"418","author":"DR Paul","year":"2011","unstructured":"Paul DR. Elaborations on the Higuchi model for drug delivery. Int J Pharm. 2011;418:13\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.10.037.","journal-title":"Int J Pharm"},{"issue":"20160405","key":"1892_CR50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.carbpol.2016.03.028","volume":"147","author":"PIP Soares","year":"2016","unstructured":"Soares PIP, Sousa AI, Silva JC, et al. Chitosan-based nanoparticles as drug delivery systems for doxorubicin: Optimization and modelling. Carbohydr Polym. 2016;147(20160405):304\u201312. https:\/\/doi.org\/10.1016\/j.carbpol.2016.03.028.","journal-title":"Carbohydr Polym"},{"key":"1892_CR51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.addr.2004.09.003","volume":"57","author":"W Jiang","year":"2005","unstructured":"Jiang W, Gupta RK, Deshpande MC, et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57:391\u2013410. https:\/\/doi.org\/10.1016\/j.addr.2004.09.003.","journal-title":"Adv Drug Deliv Rev"},{"key":"1892_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.polymdegradstab.2015.04.025","volume":"119","author":"H Keles","year":"2015","unstructured":"Keles H, Naylor A, Clegg F, et al. Investigation of factors influencing the hydrolytic degradation of single PLGA microparticles. Polym Degrad Stab. 2015;119:228\u201341.","journal-title":"Polym Degrad Stab"},{"key":"1892_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s42765-020-00031-1","volume":"2","author":"H Bukhary","year":"2020","unstructured":"Bukhary H, Williams GR, Orlu M. Fabrication of electrospun levodopa-carbidopa fixed-dose combinations. Adv Fiber Mater. 2020;2:194\u2013203.","journal-title":"Adv Fiber Mater"},{"key":"1892_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-3155-10-20","volume":"10","author":"N Pirooznia","year":"2012","unstructured":"Pirooznia N, Hasannia S, Lotfi AS, et al. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. J Nanobiotechnol. 2012;10:20. https:\/\/doi.org\/10.1186\/1477-3155-10-20.","journal-title":"J Nanobiotechnol"},{"key":"1892_CR55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.15171\/apb.2019.068","volume":"9","author":"G Mohammadi","year":"2019","unstructured":"Mohammadi G, Mirzaeei S, Taghe S, et al. Preparation and Evaluation of Eudragit(R) L100 Nanoparticles Loaded Impregnated with KT Tromethamine Loaded PVA -HEC Insertions for Ophthalmic Drug Delivery. Adv Pharm Bull. 2019;9:593\u2013600. https:\/\/doi.org\/10.15171\/apb.2019.068.","journal-title":"Adv Pharm Bull"},{"key":"1892_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0928-0987(97)00075-4","volume":"6","author":"K Edsman","year":"1998","unstructured":"Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci. 1998;6:105\u201312. https:\/\/doi.org\/10.1016\/s0928-0987(97)00075-4.","journal-title":"Eur J Pharm Sci"},{"key":"1892_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s0928-0987(97)00074-2","volume":"6","author":"J Carlfors","year":"1998","unstructured":"Carlfors J, Edsman K, Petersson R, et al. Rheological evaluation of Gelrite in situ gels for ophthalmic use. Eur J Pharm Sci. 1998;6:113\u20139. https:\/\/doi.org\/10.1016\/s0928-0987(97)00074-2.","journal-title":"Eur J Pharm Sci"},{"key":"1892_CR58","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/app.35584","volume":"125","author":"B Wang","year":"2012","unstructured":"Wang B, Cao Y, Yang L, et al. Rheological properties of PLGA-PEG\u2010PLGA copolymers for ophthalmic injection. J Appl Polym Sci. 2012;125:370\u20135.","journal-title":"J Appl Polym Sci"},{"key":"1892_CR59","doi-asserted-by":"publisher","unstructured":"Camargo JA, Sapin A, Nouvel C et al. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization. Drug Dev Ind Pharm. 2013;39:146\u2013155. 20120308. https:\/\/doi.org\/10.3109\/03639045.2012.660952","DOI":"10.3109\/03639045.2012.660952"},{"key":"1892_CR60","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ejps.2008.12.003","volume":"36","author":"W Rungseevijitprapa","year":"2009","unstructured":"Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci. 2009;36:524\u201353120081214. https:\/\/doi.org\/10.1016\/j.ejps.2008.12.003.","journal-title":"Eur J Pharm Sci"},{"key":"1892_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2018.03.003","volume":"276","author":"Q Bao","year":"2018","unstructured":"Bao Q, Newman B, Wang Y, et al. In vitro and ex vivo correlation of drug release from ophthalmic ointments. J Controlled Release. 2018;276:93\u2013101.","journal-title":"J Controlled Release"},{"key":"1892_CR62","doi-asserted-by":"publisher","first-page":"14512","DOI":"10.1038\/s41598-021-93785-6","volume":"11","author":"CE Rapier","year":"2021","unstructured":"Rapier CE, Shea KJ, Lee AP. Investigating PLGA microparticle swelling behavior reveals an interplay of expansive intermolecular forces. Sci Rep. 2021;11:14512. https:\/\/doi.org\/10.1038\/s41598-021-93785-6.","journal-title":"Sci Rep"},{"key":"1892_CR63","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1039\/c9bm01799b","volume":"8","author":"D Tian","year":"2020","unstructured":"Tian D, Xu H, Xiao B, et al. Single-step formulation of levodopa-based nanotheranostics - strategy for ultra-sensitive high longitudinal relaxivity MRI guided switchable therapeutics. Biomater Sci. 2020;8:1615\u201321. https:\/\/doi.org\/10.1039\/c9bm01799b.","journal-title":"Biomater Sci"},{"key":"1892_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1023\/a:1007582911958","volume":"17","author":"K Fu","year":"2000","unstructured":"Fu K, Pack DW, Klibanov AM, et al. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res. 2000;17:100\u20136. https:\/\/doi.org\/10.1023\/a:1007582911958.","journal-title":"Pharm Res"},{"key":"1892_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WNF.0000000000000126","volume":"39","author":"HM Yao","year":"2016","unstructured":"Yao HM, Hsu A, Gupta S, et al. Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers. Clin Neuropharmacol. 2016;39:10\u20137. https:\/\/doi.org\/10.1097\/WNF.0000000000000126.","journal-title":"Clin Neuropharmacol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01892-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01892-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01892-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:59:59Z","timestamp":1759928399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01892-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01892-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"26 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}